Clinical Research Directory
Browse clinical research sites, groups, and studies.
SBRT With Atezo/Bev for HCC
Sponsor: Abramson Cancer Center at Penn Medicine
Summary
A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with concurrent atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma (HCC)
Official title: A Phase I Study of SBRT Vaccination With Atezolizumab and Bevacizumab for Patients With Advanced Hepatocellular Carcinoma
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2022-09-01
Completion Date
2026-12-31
Last Updated
2026-02-20
Healthy Volunteers
No
Conditions
Interventions
SBRT + atezolizumab and bevacizumab
Stereotactic Body Radiotherapy (SBRT) is a radiation procedure that delivers precise doses of radiation in fractions. See following section for more information on the schedule, dose, volume, and simulation of SBRT. Atezolizumab is an FDA-approved immune checkpoint inhibitor that is used in the treatment of advanced HCC. It is administered as a flat-dose 1200 mg intravenous infusion every three weeks. Bevacizumab is an FDA-approved anti-VEGF monoclonal antibody that is used in the treatment of advanced HCC in combination with atezolizumab. It is administered as a weight-based dose of 15 mg/kg intravenous infusion every 3 weeks.
Locations (1)
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States